Drawing for PRINTORGANS

USPTO serial 98638835

PRINTORGANS

Reviewed by CopyMark Law Group

Filing date
Status date
Registration date
—
Examiner
LEASER, ANDREW C
Law office
TMO LAW OFFICE 117

What this means

These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.

Status 602: These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances.

Need help with PRINTORGANS?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Jared L. DuJack

Jared L. DuJack Schmeiser, Olsen & Watts, LLP22 Century Hill Drive, Suite 302Latham, NY 12110United States

Goods and services

ClassDescriptionStatusFirst use
005Bioprinted organs comprising primarily living tissue for medical use; Bioprinted organs, namely ears comprising primarily living tissue for medical use; Bioprinted organs, namely, livers comprising primarily living tissue for medical use; Bioprinted organs, namely, kidneys comprising primarily living tissue for medical use; Bioprinted organs, namely portions of ears comprising primarily living tissue for medical use; Bioprinted organs, namely, portions of livers comprising primarily living tissue for medical use; Bioprinted organs, namely, portions of kidneys comprising primarily living tissue for medical use; Autologous bioprinted organs comprising primarily living tissue for medical use; Autologous bioprinted organs, namely, ears comprising primarily living tissue for medical use; Autologous bioprinted organs, namely, livers comprising primarily living tissue for medical use; Autologous bioprinted organs, namely, kidneys comprising primarily living tissue for medical use; Autologous bioprinted organs, namely, portions of ears comprising primarily living tissue for medical use; Autologous bioprinted organs, namely, portions of livers comprising primarily living tissue for medical use; Autologous bioprinted organs, namely, portions of kidneys comprising primarily living tissue for medical use; Bioprinted structures for organs comprising primarily living tissue for medical use; Autologous bioprinted structures for organs comprising primarily living tissue for medical use; Ink for 3D bioprinters comprising primarily living cells or other biological materials for medical purposesACTIVE—
0073D bioprinters; 6-axis 3D bioprintersACTIVE—
010Bioprinted organs comprising primarily synthetic material for medical use; Bioprinted organs, namely ears comprising primarily synthetic material for medical use; Bioprinted organs, namely, livers comprising primarily synthetic material for medical use; Bioprinted organs, namely, kidneys comprising primarily synthetic material for medical use; Bioprinted organs, namely portions of ears comprising primarily synthetic material for medical use; Bioprinted organs, namely, portions of livers comprising primarily synthetic material medical use; Bioprinted organs, namely, portions of kidneys comprising primarily synthetic material for medical use; Autologous bioprinted organs comprising primarily synthetic material for medical use; Autologous bioprinted organs, namely, ears comprising primarily synthetic material for medical use; Autologous bioprinted organs, namely, livers comprising primarily synthetic material for medical use; Autologous bioprinted organs, namely, kidneys comprising primarily synthetic material for medical use; Autologous bioprinted organs, namely, portions of ears comprising primarily synthetic material for medical use; Autologous bioprinted organs, namely, portions of livers comprising primarily synthetic material for medical use; Autologous bioprinted organs, namely, portions of kidneys comprising primarily synthetic material for medical use; Bioprinted structures for organs comprising primarily synthetic material for medical use; Autologous bioprinted structures for organs comprising primarily synthetic material for medical use; Ink for 3D bioprinters comprising primarily synthetic material or other biological materials for medical purposesACTIVE—
044Medical services, namely, organ replacement therapy; Medical services, namely, on demand organ replacement therapy; Medical services, namely, on demand organ replacement therapy using 3D bioprinting; Medical services, namely, on demand organ replacement therapy using autologous bioprintingACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB2): The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.

DateCodeEventWhat it means
Oct 9, 2026MAB2ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPONDThe trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.
Oct 9, 2026ABN2ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSEThe trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.
Mar 27, 2026GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Mar 27, 2026GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Mar 27, 2026CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Feb 27, 2026TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Feb 27, 2026CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Feb 27, 2026ERFRTEAS REQUEST FOR RECONSIDERATION RECEIVED—
Dec 2, 2025XELGAPPLICATION EXTENSION GRANTED/RECEIPT PROVIDED—
Dec 2, 2025XELRAPPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED—
Sep 2, 2025GNFNNOTIFICATION OF FINAL REFUSAL EMAILED—
Sep 2, 2025GNFRFINAL REFUSAL E-MAILEDA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Sep 2, 2025CNFRFINAL REFUSAL WRITTENA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Aug 8, 2025TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Aug 8, 2025CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Aug 8, 2025TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
May 8, 2025XELGAPPLICATION EXTENSION GRANTED/RECEIPT PROVIDED—
May 8, 2025XELRAPPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED—
Feb 8, 2025GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Feb 8, 2025GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Feb 8, 2025CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Feb 1, 2025DOCKASSIGNED TO EXAMINER—
Jan 31, 2025NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Jul 9, 2024NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance